Related Experiment Videos
[Changes in fibrinolysis-associated parameters in HELLP syndrome]
M Kolben1, A Lopens, M Schmitt
1Frauenklinik Technischen Universität München, Klinikum rechts der Isar.
Geburtshilfe Und Frauenheilkunde
|May 1, 1994
Summary
HELLP syndrome patients show increased levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in plasma, suggesting endothelial damage and impaired fibrinolysis in this condition.
Area of Science:
- Obstetrics and Gynecology
- Hematology
- Pathophysiology
Context:
- HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a severe pregnancy complication.
- Fibrinolysis, the breakdown of blood clots, plays a crucial role in pregnancy health.
- Understanding the role of fibrinolytic parameters in HELLP syndrome is vital for diagnosis and management.
Purpose:
- To investigate plasma and placental fibrinolytic parameters in patients with HELLP syndrome.
- To compare these parameters with those of healthy pregnant women.
Summary:
- Patients with HELLP syndrome exhibited significantly higher plasma concentrations of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) compared to controls.
- No significant differences were observed in plasma levels of urokinase plasminogen activator (uPA), uPA-receptor, or D-dimer.
- Placental tissue analysis revealed limited significant differences in these fibrinolytic markers.
Impact:
- Findings suggest endothelial damage and tPA release may contribute to HELLP syndrome pathophysiology.
- Elevated PAI-1 levels may indicate deficient fibrinolysis, potentially impairing microcirculation.
- Further research is needed to explore the clinical relevance of tPA and PAI-1 as predictors of hypertensive pregnancy disorders.